Inventor · disambiguated record
Changyu Wang
Also filed as: WANG CHANGYU
29 granted patents·22 pending applications·5,869 citations·filing 2003–2025
98Inventor score
Files withBRISTOL MYERS SQUIBB CO17SQUIBB & SONS LLC14MEDAREX INC4KEYMED BIOSCIENCES CO LTD3DESHPANDE SHRIKANT2
Top patents by PatentIndex Score
51 records- 0199US10441655B2Monoclonal antibodies to programmed death 1 (PD-1)SQUIBB & SONS LLC·Filed 2016·Granted Oct 15, 2019·25 cites·22 claims
- 0299US9580507B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2016·Granted Feb 28, 2017·129 cites·30 claims
- 0399US9492539B2Monoclonal antibodies to Programmed Death 1 (PD-1)SQUIBB & SONS LLC·Filed 2014·Granted Nov 15, 2016·119 cites·65 claims
- 0499US9492540B2Methods for treating cancer using anti-PD-1 antibodiesSQUIBB & SONS LLC·Filed 2014·Granted Nov 15, 2016·139 cites·79 claims
- 0599US9387247B2Monoclonal antibodies to programmed death 1 (PD-1)SQUIBB & SONS LLC·Filed 2014·Granted Jul 12, 2016·124 cites·45 claims
- 0699US9358289B2Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodiesSQUIBB & SONS LLC·Filed 2014·Granted Jun 7, 2016·137 cites·49 claims
- 0799US9273135B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2015·Granted Mar 1, 2016·109 cites·30 claims
- 0899US9102725B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2013·Granted Aug 11, 2015·120 cites·31 claims
- 0999US8383796B2Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2011·Granted Feb 26, 2013·355 cites·31 claims
- 1099US8008449B2Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeuticsMEDAREX INC·Filed 2006·Granted Aug 30, 2011·2.2k cites·23 claims
- 1199US7943743B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2006·Granted May 17, 2011·1.5k cites·26 claims
- 1298US9580505B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2015·Granted Feb 28, 2017·37 cites·41 claims
- 1398US9228016B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 5, 2016·85 cites·19 claims
- 1498US9084776B2Methods for treating cancer using anti-PD-1 antibodiesMEDAREX LLC·Filed 2014·Granted Jul 21, 2015·203 cites·9 claims
- 1598US8779105B2Monoclonal antibodies to programmed death 1 (PD-1)KORMAN ALAN J·Filed 2011·Granted Jul 15, 2014·479 cites·30 claims
- 1697US10501550B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 10, 2019·9 cites·58 claims
- 1797US10465010B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Nov 5, 2019·9 cites·15 claims
- 1897US9745379B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Aug 29, 2017·11 cites·58 claims
- 1996US8263073B2Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereofKORMAN ALAN·Filed 2009·Granted Sep 11, 2012·50 cites·4 claims
- 2094US11084881B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Aug 10, 2021·3 cites·19 claims
- 2193US11213586B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 4, 2022·5 cites·14 claims
- 2292US10690674B2Anti-GITR antibodies for cancer diagnosticsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 23, 2020·5 cites·27 claims
- 2392US8258266B2IP-10 antibodies and their usesDESHPANDE SHRIKANT·Filed 2009·Granted Sep 4, 2012·28 cites·17 claims
- 2488US2024158524A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2586US2023272079A1Monoclonal Antibodies to Programmed Death 1 (PD-1)SQUIBB & SONS LLC·Filed 2023·Application pending·0 cites
- 2684US11408889B2Anti-GITR antibodies for cancer diagnosticsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Aug 9, 2022·1 cites·20 claims
- 2783US2023287064A1Enhancing anti-cancer activity of immunomodulatory fc fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2882US2023061544A1Human monoclonal antibodies to programmed death ligand 1 (pd-l1)SQUIBB & SONS LLC·Filed 2022·Application pending·0 cites
- 2979US2023050665A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 3079US2020138945A1Monoclonal Antibodies to Programmed Death 1 (PD-1)SQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 3177US11802162B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 31, 2023·0 cites·25 claims
- 3274US8945546B2IP-10 antibodies and their usesDESHPANDE SHRIKANT·Filed 2012·Granted Feb 3, 2015·2 cites·21 claims
- 3374US2025236650A1Enhancing anti-cancer activity of immunomodulatory fc fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 3473US9994633B2IP-10 antibodies and their usesSQUIBB & SONS LLC·Filed 2014·Granted Jun 12, 2018·1 cites·4 claims
- 3571US2022175921A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 3671US2020062848A1Human monoclonal antibodies to programmed death ligand 1 (pd-l1)SQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 3770US2020207816A1Enhancing anti-cancer activity of immunomodulatory fc fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 3869US2025346685A1Bispecific antibody and use thereofKEYMED BIOSCIENCES CHENGDU CO LTD·Filed 2025·Application pending·0 cites
- 3969US2018312553A1Enhancing anti-cancer activity of immunomodulatory fc fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 4064US2017158767A1Human monoclonal antibodies to programmed death ligand 1 (pd-l1)SQUIBB & SONS LLC·Filed 2017·Application pending·0 cites
- 4164US2024002540A1Bispecific antibody and use thereofKEYMED BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 4263US2025215097A1Development and use of novel immunomodulatorBEIJING TIANNUOJIANCHENG PHARMA TECH CO LTD·Filed 2023·Application pending·0 cites
- 4361US2015322119A1Enhancing anti-cancer activity of immunomodulatory fc fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 4457US2005191293A1IP-10 antibodies and their usesFiled 2004·Application pending·0 cites
- 4554US2024247072A1Development and use of function-enhanced antibody blocking agentKEYMED BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 4654US2024067751A1Development and application of complement inhibitorKEYMED BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 4751US11103956B2Double-side synchronous laser shock peening method for leading edge of turbine bladeUNIV JIANGSU·Filed 2017·Granted Aug 31, 2021·0 cites·13 claims
- 4849US2003165499A1Compositions and methods for treating psoriasisFiled 2003·Application pending·0 cites
- 4946US2011091472A1Compositions for treating psoriasisNOVARTIS VACCINES & DIAGNOSTIC·Filed 2010·Application pending·0 cites
- 5043US11342099B2Laser shock peening method for improving the corrosion resistance of sintered Nd—Fe—B magnetUNIV JIANGSU·Filed 2018·Granted May 24, 2022·0 cites·4 claims
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Changyu Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →